Auro Laboratories Ltd vs Sanofi Consumer Healthcare India Ltd Stock Comparison
Auro Laboratories Ltd vs Sanofi Consumer Healthcare India Ltd Stock Comparison
Last Updated on: May 18, 2026
Key Highlights
The Latest Trading Price of Auro Laboratories Ltd is ₹ 267.25 as of 18 May 15:30
. The P/E Ratio of Auro Laboratories Ltd changed from 7 on March 2021 to 0 on December 2024 . This represents a CAGR of -100.00% over 7 yearsThe P/E Ratio of Sanofi Consumer Healthcare India Ltd changed from 62.6 on December 2024 to 62.6 on December 2024 . This represents a CAGR of 0.00% over 1 years The Market Cap of Auro Laboratories Ltd changed from ₹ 50.55 crore on March 2021 to ₹ 0 crore on December 2024 . This represents a CAGR of -100.00% over 7 yearsThe Market Cap of Sanofi Consumer Healthcare India Ltd changed from ₹ 11347 crore on December 2024 to ₹ 11347 crore on December 2024 . This represents a CAGR of 0.00% over 1 years The revenue of Auro Laboratories Ltd for the Sep '25 is ₹ 9.81 crore as compare to the Jun '25 revenue of ₹ 3.19 crore. This represent the growth of 207.52% The revenue of Sanofi Consumer Healthcare India Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Auro Laboratories Ltd for the Sep '25 is ₹ 3.33 crore as compare to the Jun '25 ebitda of ₹ 0.45 crore. This represent the growth of 640% The ebitda of Sanofi Consumer Healthcare India Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Auro Laboratories Ltd changed from ₹ 0.75 crore to ₹ 0.72 crore over 4 quarters. This represents a CAGR of -4.00%
The net profit of Sanofi Consumer Healthcare India Ltd changed from ₹ 0 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of 0.0%
The Dividend Payout of Auro Laboratories Ltd changed from 0 % on March 2021 to 0 % on December 2024 . This represents a CAGR of 0.0% over 7 yearsThe Dividend Payout of Sanofi Consumer Healthcare India Ltd changed from 6.06 % on December 2023 to 69.89 % on December 2024 . This represents a CAGR of 239.60% over 2 years .
About Auro Laboratories Ltd
Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API).
Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes.
The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra.
The facility has all the required certifications from Indian authorities and European registration organization
Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA.
The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments.
About Sanofi Consumer Healthcare India Ltd
Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023, as part of Sanofi's global strategy to establish a standalone Consumer Healthcare business.
This strategic move resulted in the demerger of the Consumer Healthcare business from Sanofi India Limited (SIL) into the Company through a Scheme of Arrangement, thereby creating a distinct legal entity.
The Scheme of Arrangement, which was sanctioned by the National Company Law Tribunal, Mumbai (NCLT) enabled the seamless transfer and vesting of all assets, liabilities, and operations of SIL to the Company.
Pursuant to the Scheme becoming effective, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of Arrangement and became effective from June 1, 2024.
FAQs for the comparison of Auro Laboratories Ltd and Sanofi Consumer Healthcare India Ltd
Which company has a larger market capitalization, Auro Laboratories Ltd or Sanofi Consumer Healthcare India Ltd?
Market cap of Auro Laboratories Ltd is 166 Cr while Market cap of Sanofi Consumer Healthcare India Ltd is 11,059 Cr
What are the key factors driving the stock performance of Auro Laboratories Ltd and Sanofi Consumer Healthcare India Ltd?
The stock performance of Auro Laboratories Ltd and Sanofi Consumer Healthcare India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Auro Laboratories Ltd and Sanofi Consumer Healthcare India Ltd?
As of May 18, 2026, the Auro Laboratories Ltd stock price is INR ₹267.25. On the other hand, Sanofi Consumer Healthcare India Ltd stock price is INR ₹4802.25.
How do dividend payouts of Auro Laboratories Ltd and Sanofi Consumer Healthcare India Ltd compare?
To compare the dividend payouts of Auro Laboratories Ltd and Sanofi Consumer Healthcare India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.